Navigation Links
New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Date:8/19/2007

Findings Represent Strongest Support for Coiling Since Groundbreaking 2002

Trial

DANA POINT, Calif., Aug. 1 /PRNewswire/ -- A new study reveals that coiling, a minimally invasive procedure to treat aneurysms in the brain, is successful in preventing recurrent or first-time bleeding years after initial treatment in those aneurysms considered "untouchable" by the traditional surgical option. One of the most significant findings since the 2002 release of the International Subarachnoid Aneurysm Trial or ISAT (the trial that established coiling as a safe and effective treatment), this new study's scientific value is reflected in its large patient population and length of post-procedural follow-up -- two factors that have not existed together in other post-ISAT studies to date. Results were unveiled yesterday at the fourth Annual Meeting of the American Society of Interventional & Therapeutic Neuroradiology (ASITN) in Dana Point, California.

"This study represents a unique contribution to the scientific evidence that proves coiling to be a viable treatment option," said study presenter Jo Peluso, a neurointerventional radiologist who collected and analyzed the data on behalf of colleagues W.J.J. van Rooij and M. Sluzewski, who have been performing neurointerventional procedures since the early 1990s at Saint Elisabeth Hospital in Tilburg, the Netherlands. "The clinical credibility of any procedure relies not only on the initial trials that may sanction its use on patients, but also - and perhaps equally as important - on those long-term follow-up studies that prove the procedure's success over time. This study achieves one such milestone."

A retrospective analysis, the study includes 154 consecutive patients who underwent coiling over an 11-year period (January 1995 - August 2006) on aneurysms on the tip of the basilar artery, located in front of the brain stem. Comprising approximately 8.4 percent of all brain a
'/>"/>

SOURCE American Society of Interventional & Therapeutic
Neuroradiology

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Recently published clinical studies ... the already substantial database of evidence. This data has ... Stretta therapy for sufferers of refractory GERD. ... evidence supporting Stretta therapy as a safe and ... make Stretta therapy available to nearly 50 million Americans. ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2
... , , , ... CXM ) today announced that all patients enrolled in ... evaluation period and that it plans to provide detailed safety and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) , , The Phase ...
... , , , RIDGEFIELD, ... (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) ... (ESC) Congress in Barcelona on Sunday, Aug. 30. The ... efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, ...
Cached Medicine Technology:Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 8Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7
(Date:10/22/2014)... Hay House is pleased to announce the official release ... (Paperback; $10.82) written by the highly esteemed Tommy Rosen, leader ... is meant to help readers of all kinds end their ... Recovery 2.0 is not the average self-help book, or a ... for what comes next. For many, Alcoholics Anonymous ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that ... trouble finding time within their busy schedules for exercise and fitness. ... time to get in shape. Here are five ways you can ... , Change Up Your Commute , Consider riding a bike or ... into your daily routine. If you must use your car to ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Two sisters ... and heart damage. Ilina and Medha Krishen use ... for sounds of trouble in breathing patterns or heartbeats. ... School in Michigan, wanted to find a way to ... air pollutants. Using an electronic stethoscope, Ilina recorded one ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... webcast of surgical procedure to be held Thursday, January 17, at ... ... 10 Cardica, Inc.,(Nasdaq: CRDC ) today announced that leading ... in Nashville will,webcast a live off-pump coronary artery bypass graft (CABG) ...
... suggests it results in poor screening, prevention efforts , MONDAY, ... may be less likely to report a family history of ... strategies for that group of patients, a new study says. ... Cancer , Dr. Heather Orom, of the Barbara Ann Karmanos ...
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... (Pink Sheets: HRAL) --,HearAtLast Holdings, Inc. is proud to ... Canada (NYSE: WMT ) to open its 16th ... at 255 Silver Linden,Dr. in Richmond Hill, Ontario. The ... 8, 2007. This expansion is a direct result of,the ...
... digital identity and signature standard being adopted worldwide by, pharmaceutical ... ... digital identities, CHICAGO, Dec. 10 ... leader specializing in,authentication, software DRM and content security, today announced ...
... Brings Diverse Expertise, MIAMI, Dec. 9 ... healthcare providers, is pleased,to announce that Lisa Lopez ... Resources. Ms. Lopez was most recently Human Resources ... Her 17-year career began,in Human Resources shortly after ...
Cached Medicine News:Health News:Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery 2Health News:Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery 3Health News:Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery 4Health News:Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery 5Health News:Immigrants Less Likely to Report Family History of Cancer 2Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 2Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 3Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 4Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 2Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 3Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 4Health News:Novis Pharmaceuticals Hires Lisa Lopez 2
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: